RESEARCH PAPER

Different *in vitro* and *in vivo* profiles of substituted 3-aminopropylphosphinate and 3-aminopropyl(methyl)phosphinate GABA_B receptor agonists as inhibitors of transient lower oesophageal sphincter relaxation

A Lehmann¹, M Antonsson¹, A Aurell-Holmberg¹, LA Blackshaw^{2†}, L Brändén¹, T Elebring¹, J Jensen¹, L Kärrberg¹, JP Mattsson^{1,*}, K Nilsson¹, SS Oja³, P Saransaari⁴ and S von Unge¹

¹AstraZeneca R&D, Mölndal, Sweden, and ²Nerve Gut Research Laboratory, Hanson Institute, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, and University of Adelaide, South Australia, Australia, and ³Department of Paediatrics, Tampere University Hospital, Finland, and ⁴Brain Research Center, Medical School, University of Tampere, Finland

Correspondence

Anders Lehmann, AstraZeneca R&D, SE-431 83 Mölndal, Sweden. E-mail: Anders.Lehmann@astrazeneca.com

*Present addresses: Albireo AB, Göteborg, Sweden;

†Wingate Institute for Neurogastroenterology, Centre for Digestive Diseases, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Keywords

GABA_B receptor; transient lower oesophageal sphincter relaxation; gastro-oesophageal reflux disease; GABA transporter; hypothermia

Received

15 February 2011

Revised

27 May 2011; 6 July 2011

Accepted

12 July 2011

BACKGROUND AND PURPOSE

Gastro-oesophageal reflux is predominantly caused by transient lower oesophageal sphincter relaxation (TLOS) and GABA_B receptor stimulation inhibits TLOS. Lesogaberan produces fewer CNS side effects than baclofen, which has been attributed to its affinity for the GABA transporter (GAT), the action of which limits stimulation of central GABA_B receptors. To understand the structure–activity relationship for analogues of lesogaberan (3-aminopropylphosphinic acids), and corresponding 3-aminopropyl(methyl)phosphinic acids, we have compared representatives of these classes in different *in vitro* and *in vivo* models.

EXPERIMENTAL APPROACH

The compounds were characterized in terms of GABA_B agonism *in vitro*. Binding to GATs and cellular uptake was done using rat brain membranes and slices respectively. TLOS was measured in dogs, and CNS side effects were evaluated as hypothermia in mice and rats.

KEY RESULTS

3-Aminopropylphosphinic acids inhibited TLOS with a superior therapeutic index compared to 3-aminopropyl(methyl)phosphinic acids. This difference was most likely due to differential GAT-mediated uptake into brain cells of the former but not latter. In agreement, 3-aminopropyl(methyl)phosphinic acids were much more potent in producing hypothermia in rats even when administered i.c.v.

CONCLUSIONS AND IMPLICATIONS

An enhanced therapeutic window for 3-aminopropylphosphinic acids compared with 3-aminopropyl(methyl)phosphinic acids with respect to inhibition of TLOS_R was observed and is probably mechanistically linked to neural cell uptake of the former but not latter group of compounds. These findings offer a platform for discovery of new GABA_B receptor agonists for the treatment of reflux disease and other conditions where selective peripheral GABA_B receptor agonism may afford therapeutic effects.

Abbreviations

FLIPR, fluorescence image plate reader; GAT, GABA transporter; GORD, gastro-oesophageal reflux disease; i.g., intragastric; LOS, lower oesophageal sphincter; SAR, structure–activity relationship; TLOS_R, transient lower oesophageal sphincter relaxation

Introduction

Transient lower oesophageal sphincter relaxation (TLOS_R) has been identified as the major mechanical factor behind gastro-oesophageal reflux (Mittal *et al.*, 1995) and is therefore of great importance in the pathophysiology of gastro-oesophageal reflux disease (GORD). Although it can be triggered spontaneously at a low rate, TLOS_R typically occurs post-prandially as a result of gastric distention (Mittal *et al.*, 1995). This stimulus causes gastric vagal mechanoreceptors to fire, which is followed by excitation of brainstem vagal motoneurons. The subsequent efferent signal powerfully activates enteric inhibitory neurons that relax the smooth muscle cells of the lower oesophageal sphincter (LOS). While gastric distension is the principal driver of TLOS_Rs, several factors appear to modulate them. These include posture (van Wijk *et al.*, 2010), adiposity (Wu *et al.*, 2007), intragastric (i.g.) pH (Stakeberg and Lehmann, 1999) and colonic feedback (Piche *et al.*, 2000). A promising therapeutic strategy in the treatment of GORD is therefore to reduce the excitability of afferent vagal fibres, and this has been successfully accomplished with GABA_B receptor agonists such as baclofen (Lehmann *et al.*, 2010). However, baclofen produces a number of central side effects and is not an agent recommended in the management of GORD. In some patients, a low basal LOS pressure accounts for significant reflux (van Herwaarden *et al.*, 2000). Notably, GABA_B receptor agonists elevate basal LOS pressure in humans (in contrast to dogs or ferrets; reviewed by Lehmann *et al.*, 2010) so GABA_B receptor agonists may reduce reflux through two mechanisms.

We have discovered that the substituted 3-aminopropylphosphinic acid (2*R*)-(3-amino-fluoropropyl) phosphinic acid (AZD3355, lesogaberan, compound 10 in Figure 1) reduces the incidence of TLOS_R and reflux in dogs with a broader therapeutic window than baclofen (Alstermark *et al.*, 2008; Lehmann *et al.*, 2009; Brändén *et al.*, 2010). This differentiation was attributed to the affinity of lesogaberan but not baclofen for the GABA transporter (GAT) in the CNS (Lehmann *et al.*, 2009). Lesogaberan has been shown to reduce TLOS_R in healthy volunteers (Boeckxstaens *et al.*, 2010b) and to inhibit both TLOS_Rs and reflux episodes as measured with pHmetry and impedance in GORD patients not responding fully to proton pump inhibitors (the target patient population for reflux inhibitors; Boeckxstaens *et al.*, 2010a). Importantly, a 1 month phase IIa study demonstrated symptomatic relief in GORD patients with a partial response

to proton pump inhibitors with an acceptable side effect profile (Boeckxstaens *et al.*, 2011).

The potential of discovering novel GABA_B receptor agonists in the 3-aminopropylcarboxylic acid class may have been exhausted from a drug discovery viewpoint. However, 3-aminopropyl(methyl)phosphinic acids are more interesting in this context, and their effect on TLOS_R has not been assessed in any detail with the exception of 3-aminopropyl(methyl)phosphinic acid (SK&F97541; Blackshaw *et al.*, 1999). The primary goal of the current investigation was to compare 3-aminopropylphosphinic and 3-aminopropyl(methyl)phosphinic acids as reflux inhibitors. The structure–activity relationship (SAR) for most of the compounds used in the present study with respect to affinity for and activation of the GABA_B receptor has been published before (Alstermark *et al.*, 2008). There is a reasonable correlation both for 3-aminopropylphosphinic and for 3-aminopropyl(methyl)phosphinic acids between the affinity for the native rat GABA_B receptor and the agonistic potency on the human recombinant GABA_{B(1a)}–GABA_{B(2)} receptor. Both the 3-aminopropylphosphinic and 3-aminopropyl(methyl)phosphinic acids are full agonists at the GABA_B receptor (Alstermark *et al.*, 2008). In general, there are no major differences in either affinity or potency between the 3-aminopropylphosphinic acids and the corresponding 3-aminopropyl(methyl)phosphinic acids. One exception is the 2-keto substituted analogues where the 3-aminopropyl(methyl)phosphinic acid displays lower affinity and potency than the corresponding 3-aminopropylphosphinic acid (Alstermark *et al.*, 2008).

In the current study, particular emphasis was placed on the therapeutic index of the compounds. Since it was found that 3-aminopropylphosphinic acids carrying a small (O, OH, F) but not large (4-chlorophenyl, 5-chlorothieryl) substituent in the 2-position had a superior therapeutic margin, we next determined whether this was related to intracellular uptake in the CNS secondary to binding to the GAT. The selection of compounds to evaluate in this context is fairly narrow since most modifications of the 3-aminopropyl backbone render the molecules inactive at the GABA_B receptor (Froestl *et al.*, 1995; Alstermark *et al.*, 2008). The results of this study helped us to delineate a SAR for these two groups of compounds as regards the therapeutic index, and based on their functional differences, we now refer to them as group I (3-aminopropyl(methyl)phosphinic acids and 3-aminopropylphosphinic acids with a large substituent in the 2-position) and group II

Figure 1

Structures of the compounds studied. The compounds are, when applicable, organized pairwise (compounds 1–14).

GABA_B agonists (3-aminopropylphosphinic acids with a small substituent in the 2-position; see Figure 1).

Methods

Animal care

Unless otherwise noted, the following applied for rodent and dog experiments. All animal care and experimental procedures were approved by the Ethical Committee for Animal Experiments of the Göteborg Region. A license (No. 31-8825/08) for housing and using laboratory animals was obtained from the Swedish Board of Agriculture, and EU directive 609/86 was followed. Dogs were housed in compatible (double) pairs in dog holding rooms. Dogs were fed complete Good Laboratory Practice fixed pelleted formula from Dechra (Uldum, Denmark). Fresh water was supplied *ad libitum* through multiple drinking nozzles in the holding room. The size of the areas the dogs accessed was above the minimum requirements of the Swedish national regulations. Temperature and humidity of the dog holding rooms were generally kept at 17–20°C and 30–60% relative humidity. The number of air changes per hour was approximately 15. The animals had daylight through windows and electric light from fluorescent lamp fittings. Light was regulated to give 12 h each of daylight and darkness (night).

Rodents were housed in solid-bottomed macrolon cages. The number of animals per cage was equal to or less than maximum number according Swedish and EU regulations on housing space requirements. The cage bottoms were covered

with aspen bedding material. Rodents received *ad libitum* pelleted rodent diet R3 from Lantmännen (Kimstad, Sweden). Municipal drinking water was available from plastic bottles with stainless steel sipper tubes. Temperature and humidity of the rodent holding rooms were generally kept at 20–23°C and 40–60% relative humidity, and the air was changed 15 times h⁻¹. Light was provided from fluorescent lamp fittings or light bulbs and regulated to give 12 h each of daylight and darkness (night).

Binding of ligands to GABA_B receptors in rat and dog brain membranes and to GABA_A receptors in rat brain membranes

The methods to assess binding to GABA receptors have been described previously (Lehmann *et al.*, 2005, 2009). In brief, binding of ligands to GABA_B receptors was determined by displacement of [³H]-GABA in the presence of isoguvacine from Sprague–Dawley rat or Beagle dog cerebocortical membranes, employing a filtration binding assay in 96-well plates.

Membranes and [³H]-GABA were incubated on a Denley microplate shaker (Colchester, UK) for 20 min at room temperature in the presence or absence of test compound, followed by rapid filtration through a glass fibre filter (Printed filtermat B filters, Wallac, Turku, Finland) using a TOMTEC cell harvester (Orange, CT). Radioactivity on the filters was determined in a Microbeta scintillation counter (Wallac). [³H]-GABA displacement curves to determine IC₅₀ values were constructed by fitting the four-parameter logistic equation to the data. K_D for GABA was determined on each preparation by homologous competition and used to calculate K_i values from

IC₅₀ determinations on that particular preparation using the Cheng–Prusoff equation (Cheng and Prusoff, 1973).

Binding to rat brain GABA_A receptors was assessed in a similar manner as for the GABA_B binding but using [³H]-muscimol as a radioligand and without the presence of isoguvacine in the incubation buffer (Lehmann *et al.*, 2005, 2009). The GABA_A/GABA_B selectivity was determined for compounds 1–2, 7–10 and 13–14.

Effect of compounds 15–19 on human GABA_{B1(a)}/GABA_{B2} receptors

The potency of GABA_B receptor agonists to stimulate intracellular calcium release was assessed in CHO-K1 cells stably co-expressing a GABA_B-G_{q15} fusion protein and GABA_{B2} using a fluorescence imaging plate reader (FLIPR; Molecular Devices, Sunnyvale, CA) as described previously (Lehmann *et al.*, 2005, 2009). Only compounds 15–19 were studied since the effects of the other agonists in this assay have been reported earlier (Alstermark *et al.*, 2008). Briefly, GABA_{B1}-G_{q15}/GABA_{B2} cells, seeded in black-walled poly-D-lysine coated 96-well plates (Becton Dickinson, Bedford, UK), were loaded with the calcium sensor dye Fluo-3. The cells were then assayed in the FLIPR in the presence or absence of test compound. The fluorescence was sampled every second for 60 s (10 s before and 50 s after the addition of test compound) and then every sixth second for 120 s. The peak response values from two to four determinations at each concentration of test compound were used to construct concentration–response curves for EC₅₀ determinations by fitting the four-parameter logistic equation to the data.

Effect of GABA_B receptor agonists on splice variants of the GABA_{B1} receptor

The human splice variants GABA_{B1(a)}, GABA_{B1(b)}, GABA_{B1(e)}, GABA_{B1(g)}, GABA_{B1(m)}, GABA_{B1(o)} and GABA_{B2} were cloned from a human brain cDNA, as specified in Lehmann *et al.* (2005) and Ekstrand (2002), and subcloned into pCI-Neo expression vectors. Transient co-transfections of GABA_{B1} splice variants and GABA_{B2} in CHO-G_{q15} cells were performed using lipofectamin (Life Technologies, Paisley, Scotland) as specified in the manufacturer's protocol. The potency of the compounds evaluated was then determined using FLIPR technology as described above. The details of these experiments have been described in Lehmann *et al.* (2009). The following pairs of group I and II agonists were tested: compounds 1 and 2, 7 and 8 as well as 13 and 14.

Sequestration of radiolabelled GABA_B receptor ligands in slices from the rat cortex

Superficial slices were manually prepared from the cerebral cortices of young adult 3 month old Wistar rats (Orion, Espoo, Finland). The experiments were made according to the EU directive 609/86 on the protection of laboratory animals. They were approved by the Tampere University Committee for Animal Experiments.

The animals were housed individually in separate cages under 12 h/12 h cycles of light and dark and received food and water *ad libitum* before the experiments. The slices were incubated for varying periods with the radioactively labelled compounds in standard Krebs–Ringer–HEPES medium con-

taining (mmol L⁻¹) NaCl 127, KCl 5, CaCl₂ 0.75, MgSO₄ 1.3, Na₂HPO₄ 1.3, HEPES 15, D-glucose 10, pH adjusted to 7.4 with 1 M NaOH. The extracellular space in the slices were estimated with [³H]-inulin, and the label retained in them was subtracted to obtain the rates of intracellular penetration of the labelled compounds.

The following isotopes were used (for structures, see Figure 1):

[³H]-compound 1, radiochemical purity 99%, specific activity 1623 kBq nmol⁻¹

[¹⁴C]-compound 4, radiochemical purity 98%, specific activity 2.06 kBq nmol⁻¹

[¹⁴C]-compound 8, radiochemical purity 92%, specific activity 2.1 kBq nmol⁻¹

[¹⁴C]-compound 12, radiochemical purity 92%, specific activity 5.8 kBq nmol⁻¹

The *in vivo* distribution of [¹⁴C]-compound 8 was also studied in the rat (supplementary information online) where emphasis was placed on the uptake into the CNS.

Binding of GABA_B receptor ligands to the rat GAT

Competition for binding to the GAT between [³H]-GABA and different GABA_B receptor agonists in Wistar rat brain membranes was investigated using the method of Shank *et al.* (1990). Binding to GABA receptors was prevented by adding muscimol (10 μM) and baclofen (10 μM), and each concentration was tested in duplicate. The following compounds were evaluated in this assay: 1–3, 8–9, 11–12 and 16.

Quantification of TLOSRS in dogs

TLOSRS were measured in adult Labrador retrievers of either gender using Dentsleeve manometry as described previously (Lehmann *et al.*, 1999).

TLOSRS were stimulated for 45 min by infusion of an acidified nutrient solution into the stomach followed by insufflation of air. As the incidence of TLOSRS varies between dogs, each animal was used as its own control. The number of acid reflux episodes was also quantified using intra-oesophageal pHmetry, but since this parameter is much more variable than TLOSRS (e.g. a reflux episode may pass undetected if a previous reflux event has acidified the oesophagus), data on reflux are not presented. All compounds were given i.g. 30 min before stimulation of TLOSRS, respectively, as indicated in Figure 5. The central channel of the Dentsleeve assembly was used for i.g. administration of drugs and liquid nutrient and for insufflation of air. The following agonists were tested in this model: 1–8, 11–12 and 15–19. The effect of compound 8 on TLOSRS was also evaluated in ferrets (supplementary information on-line).

Hypothermia after i.c.v. administration of GABA_B receptor agonists in rats

Adult female Sprague–Dawley rats (M&B A/S, Ry, Denmark) weighing 250–300 g were used in all experiments. Throughout the experiments, the animals were housed individually in the care of AstraZeneca Laboratory Animal Resources, where

they were maintained on standard light–dark cycle (12:12) and received food and water *ad libitum*.

One day before the surgical procedure, and 7 days after surgery, the animals were treated with Bactrim® (0.2 mL per animal; Roche, Stockholm, Sweden) to reduce the risk of infection. Animals were stereotactically implanted with an intracerebral microinjection guide cannula (26 gauge cannula from Plastics One, Roanoke, VA). On the day of surgery, the rats were anaesthetized with an i.p. injection of an 8:1 mixture of Ketalar® (ketamine, 50 mg·mL⁻¹, Pfizer, Sollentuna, Sweden) and Rompun® (xylazine, 20 mg·mL⁻¹, Bayer, Animal Health Care, Lyngby, Denmark) 8:1, 5 mL·kg⁻¹ and subsequently mounted in a stereotaxic apparatus (Kopf, Tujunga, CA). The stereotaxic co-ordinates for the guide cannula were 1.0 mm anterior to the bregma, 1.5 mm lateral to the sagittal suture and 4.0 mm ventral to the cortical surface (Paxinos and Watson, 1982). The guide cannula and a stainless steel screw were anchored to the skull with acrylic dental cement. After 7 days of recovery, the accuracy of the implantation was tested using the angiotensin II (Sigma, St. Louis, MO) drinking test. An i.c.v. injection of angiotensin II (100 ng per animal) was given, and animals not demonstrating a prompt and sustained drinking response were excluded. The placement of the cannula was also verified in some animals at the end of the study by the injection of Evans Blue, removal of the brain and macroscopic examination of coronal brain slices.

A temperature-sensitive microchip (Implantable Programmable Temperature Transponder, IPTT 200, PLEXX, Elst, The Netherlands) was implanted s.c. in the interscapular region in animals that passed the angiotensin II test. Compounds were administered via an internal cannula (Plastics One, Inc.) projecting 1 mm below the tip of the guide cannula. All injections were performed manually with a Hamilton microsyringe in a volume of 5 µL during 60 s. Before each i.c.v. injection, the animals temperature was monitored to set a baseline level (three measurements during 20 min). Immediately after the injections, rats were placed in their home cage, and their temperature was measured for 180 min.

All compounds were dissolved in 0.9% saline, and i.c.v. treatments were given at least 7 days apart and between 0800 h and 1400 h. The hypothermic effects of compounds 7–10 were evaluated.

Hypothermia after administration of GABA_B receptor agonists to mice

The effects of GABA_B receptor agonists on body temperature in C57Bl mice were determined using interscapular thermosensitive chips as described previously (Lehmann *et al.*, 2009). All compounds were administered s.c. For each substance and time, an exponential model, given by

$$\Delta T_{j,k} = a \cdot \exp(b \cdot \text{dose}_k) + \varepsilon_{j,k}, \quad \text{dose}_k > 0, \quad \varepsilon_{j,k} \sim N(0, \sigma^2),$$

was fitted to the data. The response $\Delta T_{j,k}$ was defined as the j^{th} mouse's temperature change from baseline adjusted with the average change from baseline of all animals that were given placebo. The baseline value was calculated as the average of all pre-drug administration data points. In this model, α represents the change from baseline for vehicle, and e^{β} denotes the change in ΔT when the dose increases with

one unit, that is, $\Delta T_k / \Delta T_{k+1}$ when $\text{dose}_{k+1} - \text{dose}_k = 1$. This model was fitted assuming homogeneous normal errors, $\varepsilon_{j,k} \sim N(0, \sigma^2)$. The model was then used to calculate ED₂, defined as the dose producing a 2°C drop in temperature, which reflects central actions of GABA_B receptor agonists. The following compounds were evaluated in the mouse hypothermia model: 1, 7–10, 13–14 and racemic baclofen. The findings on compounds 10, 14 and baclofen have been published before (Lehmann *et al.*, 2009), but they are included in the current data set to further underscore the differences between group I and II agonists.

Pharmacokinetics in dogs and rats

The purpose of the pharmacokinetic experiments was to ascertain that the kinetics (e.g. oral availability and plasma half-life) were appropriate for the pharmacodynamic experiments. A secondary aim was to determine whether there were any systematic differences between group I and II agonists that could explain any pharmacodynamic disparities. The pharmacokinetics of different GABA_B receptor agonists were determined using routine methods as described in Lehmann *et al.* (2009). Both female Sprague–Dawley rats and Labrador retrievers were used. In the rat experiments, blood was drawn from a catheter placed in the carotid artery after i.v. or i.g. dosing. Blood samples from dogs were taken from a leg vein.

Chemicals

All compounds except for compound 1 (Tocris, Bristol, UK) were synthesized at AstraZeneca R&D Mölndal or at Albany Molecular Research, Albany, NY. The synthetic procedures were according to those described in Dingwall *et al.* (1989) (compounds 2 and 18), Froestl *et al.* (1995) (compounds 3, 5 and 16), Alstermark *et al.* (2008) (compounds 4, 6, 7, 8, 9, 10, 11, 12, 13 and 14), European patent 399949 (compound 15) and US patent 6596711 (compound 17). Compound 19 was synthesized according to the procedure described for compound 18 in Dingwall *et al.* (1989) but using 2-chloro-5-(2-nitroethenyl)thiophene as starting material instead of 1-(4-chlorophenyl)-2-nitroethene. All agonists were prepared in their zwitterionic form. The radiolabelled compounds were synthesized by Roger Simonsson, AstraZeneca R&D Mölndal. The compounds were stored at room temperature protected from light, and all formulations were prepared freshly before the experiments using 0.9% NaCl as vehicle.

Selection of compounds for evaluation in different assays and models

The current series of experiments involved 19 compounds and 13 different *in vitro* assays or *in vivo* models. Obviously then, the experimental period stretched over a number of years, and therefore, not all compounds and models were available at the same time. Because of this shortcoming, selection of agonists to test had to be done based on the availability of test compound at any given time rather than on an optimal experimental strategy. In addition, due to high complexity and low yield in the synthesis of some compounds and requirement of large amounts of compounds in the dog experiments, the choice of dose levels was restricted in some cases.

Table 1GABA_B/GABA_A selectivity for four pairs of group I/II compounds

Compound	GABA _B affinity <i>K_i</i> (nM)	GABA _A affinity <i>K_i</i> (μM)	<i>K_i</i> GABA _A / <i>K_i</i> GABA _B Selectivity
1	33 ± 2.3 (87)	520 ± 43 (3)	16 000
2	15 ± 3.2 (11)	1.1 ± 0.9 (3)	70
7	200 ± 50 (11)	1 800 ± 100 (3)	9 000
8	48 ± 8.8 (12)	33 ± 7.2 (3)	690
9	4.3 ± 1.3 (3)	330 ± 22 (3)	77 000
10	5.1 ± 1.2 (10)	1.4 ± 0.3 (3)	270
13	14 ± 3.2 (9)	820 ± 11 (3)	59 000
14	10 ± 1.9 (12)	4.3 ± 0.7 (3)	430

Binding affinities (*K_i*) of ligands at the rat brain membrane GABA_B and GABA_A receptors were measured as detailed in Methods. Data are the mean ± SEM of (*n*) experiments. Results for GABA_B affinity are from Alstermark *et al.* (2008).

Nomenclature

The nomenclature regarding receptors conforms to that of The British Journal of Pharmacology's *Guide to Receptors and Channels* (Alexander *et al.*, 2011).

Statistical analysis

When appropriate, the data were analysed using Student's unpaired two-tailed *t*-test or by ANOVA followed by Hartley's sequential method of testing of individual means as indicated in the tables/figures. The null hypothesis was rejected at *P* < 0.05.

Results

Binding of GABA_B ligands to rat GABA_A and GABA_B receptors and to dog GABA_B receptors

Binding affinity to the GABA_A receptor in rat brain membranes of compounds 1–2, 7–10 and 13–14 is reported in Table 1 where data from Alstermark *et al.* (2008) on affinity for the GABA_B receptor also are given to facilitate comparison. While all compounds showed selectivity for the GABA_B receptor, the group I compounds were 1–2 orders of magnitude more selective for the GABA_B receptor than the corresponding group II analogues. Thus, methylation at the phosphorous greatly increases the selectivity for the GABA_B receptor. The IC₅₀ values for displacement of [³H]-GABA from rat brain membrane GABA_B receptors of compounds 15–19 are summarized in Table 2. In an attempt to explore SAR of 3-aminopropyl(methyl)phosphinates and 3-aminopropylphosphinates further, the hydrogen atoms at the methyl-phosphinic group were substituted by fluoro atoms. While mono-fluorination at the methyl-phosphinic group (compound 15) reduced the affinity for the rat brain GABA_B receptor by approximately three times, di-fluorination (compound 16) produced a ninefold drop in affinity. This was also found to be true after methylation of compound 13 in the 1-position (compound 17; seventeenfold less potent). Larger substituents in the 2-position of compound 2, like the

Table 2Affinity for the native rat brain GABA_B receptor and potency on the recombinant human GABA_B receptor for compounds 15–19

Compound	Binding assay GABA _B IC ₅₀ (nM)	FLIPR assay GABA _B EC ₅₀ (nM)
15	93 ± 39	80 ± 14
16	300 ± 67	370 ± 120
17	240 ± 15	440 ± 100
18	650 ± 150	150 ± 32
19	590 ± 180	350 ± 35

Binding affinities (IC₅₀) and agonistic properties (EC₅₀) of compounds at the GABA_B receptor were measured as detailed in the Methods. Data are the mean ± SEM of three independent experiments. All compounds shown in the table had an intrinsic activity = 1 with the exception of 16, which had an intrinsic activity of 0.25.

4-chlorophenyl (compound 18) or 5-chloro-2-thienyl (compound 19), decreased affinity by a factor of approximately 40.

The affinities for two pairs of group I/II GABA_B receptor agonists (compounds 3 and 4 and compounds 9 and 10, respectively) at the rat and dog receptors did not differ consistently as measured by displacement of [³H]-GABA binding from GABA_B receptor sites in brain membranes, although compound 3 had a higher, and compound 10 a lower, affinity for the dog receptor (Table 3).

Agonistic potency of compounds 15–19 on human GABA_B receptors

These five compounds all proved to be active as GABA_B receptor agonists with potencies (EC₅₀) at the human receptor, ranging from 80–440 nM and binding affinity at the rat GABA_B receptor between 93 and 650 nM (Table 2). Consequently, the activity of these agonists was high enough to justify TLOSR studies in dogs.

Table 3

Affinity for two pairs of group I/II GABA_B agonists for the native dog and rat GABA_B receptor

Compound	IC ₅₀ dog brain (nM)	IC ₅₀ rat brain (nM)
3	89 ± 6.9 (3)**	200 ± 21 (3)
4	58 ± 6.2 (4)	67 ± 6.7 (3)
9	4.6 ± 0.2 (3)	3.5 ± 1.3 (3)
10	5.7 ± 0.3 (4)**	3.6 ± 0.4 (5)

The data represent mean ± SEM; number of independent replicates is given in parentheses. **Denotes statistically significant differences ($P < 0.01$) between IC₅₀ in dog and rat brain membranes (Student's unpaired *t*-test).

Effects of group I and II agonists on splice variants of the human GABA_B receptor

Three different human GABA_{B1} receptor splice variants, GABA_{B1(a)}, GABA_{B1(b)} and GABA_{B1(e)} [also named GABA_{B1(c)}] (GenBank no AJ012187), have previously been shown to form functional heterodimers with GABA_{B2}. In addition to these, we also tested the functionality of three other putative splice variants, named GABA_{B1(g)}, GABA_{B1(m)} and GABA_{B1(o)}. All the tested splice variants were functional when co-expressed with GABA_{B2}. The agonistic activity for the 3-aminopropylphosphinates (compounds 2, 8 and 14) and corresponding 3-aminopropyl(methyl)phosphinates (compounds 1, 7 and 13) did not differ between the various splice variants (Figure 2), with the exception that there was a trend for compound 8 to be more active than compound 7 on all splice variants ($P < 0.05$ for GABA_{B1(b)}, GABA_{B1(e)} and GABA_{B1(o)}; not significant for GABA_{B1(a)}, GABA_{B1(g)} and GABA_{B1(m)}) using Student's unpaired *t*-test, in agreement with the findings of Alstermark *et al.* (2008).

Accumulation of GABA_B agonists in rat cerebrocortical slices

One group I (compound 1) and three group II (compounds 4, 8 and 12) agonists were evaluated in this assay. There was a time- and concentration-dependent uptake of the compounds, but the uptake of compound 1 was markedly lower than that of the others at all concentrations and time points (Figure 3). Among the group II agonists, the uptake of compound 4 appeared lower than that of the two other agonists.

Binding of GABA_B receptor agonists to rat brain membrane GAT

Eight GABA_B agonists (compounds 1–3, 8–9, 11–12 and 16) were characterized in the GAT rat brain membrane binding assay. While none of the group I agonists was able to displace GABA from binding to the GAT at concentrations up to 1 mM, all group II compounds produced a concentration-dependent inhibition (Figure 4), with compound 12 having the highest affinity.

TLOS in dogs

The effects of group I and II compounds are shown pairwise (when applicable) in Figure 5. In agreement with previous

Figure 2

Potencies of three pairs (A: compounds 1 and 2, B: compounds 7 and 8 and C: compounds 13 and 14) of group I/II GABA_B receptor agonists on human recombinant for GABA_B splice variants. The effects of the ligands at the GABA_{B1(a)}, GABA_{B1(b)}, GABA_{B1(e)}, GABA_{B1(g)}, GABA_{B1(m)} and GABA_{B1(o)} receptor splice variants were tested as detailed in Methods. Results are the mean ± SEM of two to three experiments; * $P < 0.05$ (Student's unpaired two-tailed *t*-test).

studies, none of the compounds studied had any effect on basal LOS pressure (data not shown; Blackshaw *et al.*, 1999; Lehmann *et al.*, 1999). Despite the finding that most group II agonists were equally or even more active at the GABA_B receptor than their corresponding group I counterpart *in vitro*, the latter were consistently much more potent and efficacious in inhibiting TLOS. For instance, while the dose of lesogabaran (compound 10) producing some 50% inhibition of TLOS approximates 7 µmol·kg⁻¹ in the dog (Lehmann *et al.*, 2009), the group I comparator compound 9 produced 51 ± 4% ($n = 4$) inhibition at 0.015 µmol·kg⁻¹. In addition, while close to full inhibition of lesogabaran is achieved at 300 µmol·kg⁻¹ (Lehmann *et al.*, 2009), compound 9 abolished TLOS at 0.15 µmol·kg⁻¹ (100 ± 0%, $n = 2$). With the limitation that some compounds only were tested at one or two doses, similar striking differences in potency and efficacy were seen for all other pairs. Interestingly, as has been reported for

Figure 3

Uptake of GABA_B receptor agonists in rat cerebrocortical slices as a function of time and concentration. Slices were incubated with radiolabelled compounds at the times and concentrations indicated, and cellular uptake was calculated from total uptake–uptake in the extracellular space. The uptake of the group I agonist compound 1 was markedly lower than that of the group II agonists compounds 4, 8 and 12 at all concentrations and times ($P < 0.01$; ANOVA followed by Hartley's sequential method of testing individual means).

lesogaberan (Lehmann *et al.*, 2009), the effects of the group II but not group I agonists appeared to reach a plateau at some 50% inhibition. Whether or not they would display biphasic dose–response curves with full inhibition at very high doses like lesogaberan (Lehmann *et al.*, 2009) was not possible to evaluate due to limited supply of the compounds.

The rank order of *in vivo* activity of the group I compounds clearly correlated with their *in vitro* activities. For example, the S-enantiomer compound 11 (EC₅₀ at the human GABA_B receptor = 1700 nM; Alstermark *et al.*, 2008) produced 60% inhibition of TLOS_R at 2.8 μmol·kg⁻¹, while the R-enantiomer compound 9 (EC₅₀ at the human GABA_B receptor = 14 nM; Alstermark *et al.*, 2008) provided 51% inhibition at 0.015 μmol·kg⁻¹. Partly due to the relative incompleteness of the dose–response curves for the group II ligands, a similar conclusion was difficult to reach for this group. However, the S-enantiomer compound 12 was less active *in vivo* than the R-enantiomer lesogaberan (Lehmann *et al.*, 2009), which is some 30 times more active *in vitro* (Alstermark *et al.*, 2008). Also, the R-enantiomer compound 6, which binds 42 times less avidly to the rat GABA_B receptor than the S-enantiomer compound 4, did not have any effect at all at 10 μmol·kg⁻¹, a dose approximating ID₅₀ for compound 4.

Of note is the observation that compounds 18 and 19 afforded 85% and 90% inhibition of TLOS_R, respectively. The efficacy of these compounds clearly suggests that they can be classified as group I agonists despite the fact that they are 3-aminopropylphosphinic acids.

None of the group I and II agonists produced any visible side effects at the doses tested. Compound 8 was also tested in ferrets with findings similar to those in dogs (supplementary material online).

Effects of i.c.v. administration of GABA_B receptor agonists on body temperature in rats

Two pairs of group I and II agonists were evaluated: compounds 7 and 8, and 9 and 10. All compounds induced a statistically significant, dose-dependent hypothermia that usually reached its nadir 30 min after administration (Figure 6). However, there was a large discrepancy between the ability of the compounds to produce hypothermia. Despite being comparably active *in vitro*, the group I agonist 7 was approximately 3 orders of magnitude more active than the corresponding group II agonist 8. There seemed to be a steep dose–response for the latter compound since there was no effect at 100 nmol, but the maximal effect was observed at 300 nmol with no further decrease at 3000 nmol. Likewise, the group I agonist 9 was 3 orders of magnitude more active than the corresponding group II agonist 10.

Hypothermic effects of GABA_B receptor agonists in mice

There was a clear relationship between the activity of GABA_B receptor agonists at the human recombinant GABA_B receptor

Figure 4

Displacement by GABA_B agonists of binding of [³H]-GABA to GAT in rat brain membranes. Note that all group II agonists (compounds with even numbers except for compound 16) were active in contrast to the group I agonists. Each concentration was tested in duplicate, and the data points represent the average.

Figure 5

Effects of GABA_B agonists on TLOS in dogs. TLOSs were scored during 45 min of gastric distension, and all drugs were administered i.g. 30 min before onset of gastric distension. Inhibition was calculated as the ratio between the number of TLOSs after drug/the number of TLOSs after vehicle as determined in separate experiments. The results represent means $\pm$ SEM; $n = 2-12$.

and their ability to induce hypothermia in mice (Figure 7). However, this relationship was only seen within the two groups of compounds. The group I agonists were considerably more active in producing a reduction in body temperature.

For instance, the group I agonist 9 was equipotent to its group II analogue 10 *in vitro*, but it was more than 3 orders of magnitude more potent at reducing body temperature in mice.

Figure 6

Effects of GABA_B agonists on body temperature in rats after i.c.v. injection. Temperature was measured telemetrically using interscapular thermosensitive chips. The results reflect means $\pm$ SEM of three to seven experiments as indicated. For some data points, SEM is not displayed since it was within the resolution of the symbol. *** P < 0.001 versus vehicle (only nadir temperature was analysed), ** P < 0.01.

Table 4

Pharmacokinetic parameters for GABA_B receptor agonists in female dogs following i.v. and p.o. dosing, individual data

Compound	Dose ($\mu\text{mol}\cdot\text{kg}^{-1}$) i.v. and p.o.	N i.v. + p.o.	CL ($\text{mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$)	$t_{1/2}$ (h)	V_{ss} ($\text{L}\cdot\text{kg}^{-1}$)	F (%)
Group II						
2	2	2 + 2	16, 25	0.51, 0.54	0.34, 0.88	8.5, 12
4	3	2 + 2	5.9, 7.5	0.37, 0.68	0.22, 0.28	82, 90
8	3	2 + 2	6.5, 10	2.5, 2.6	0.55, 0.98	55, 65
18	3	2 + 2	3.3, 4.9	2.2, 2.4	0.42, 0.58	47, 103
Group I						
3	2	2 + 2	3.5, 3.7	0.91, 1.02	0.23, 0.27	68, 77
7	1	2 + 2	2.0, 2.9	0.85, 0.94	0.15, 0.16	67, 76
13	0.5	2 + 2	2.2, 2.7	0.94, 0.95	0.16, 0.20	60, 88

CL, clearance; $t_{1/2}$, half-life; V_{ss} , volume of distribution at steady state; F, oral availability.

Figure 7

Hypothermic effects ($\log \text{ED}_2$) in mice as a function of potency on recombinant human GABA_B receptors ($\log \text{EC}_{50}$). Data on compounds 10, 14 and baclofen are from Lehmann *et al.* (2009). Note that the potency of the compounds to produce hypothermia is related to the potency at the GABA_B receptor, but that group II agonists are much less potent at inducing hypothermia than group I compounds at comparable *in vitro* potencies.

Pharmacokinetics in dogs and rats

The plasma half-life and oral availability (Table 4) of the compounds studied in dogs were compatible with a 45 min recording period of TLOS_R and with i.g. administration. There was no general difference in the pharmacokinetics in dogs (Table 4) or rats (Table 5) between 3-aminopropylphosphinic and 3-aminopropyl(methyl)phosphinic acids that could explain the disparate *in vivo* profiles. In general, oral availability was high for both classes of agonists.

Discussion and conclusions

In this study, evidence is presented to suggest that GABA_B receptor agonists with a phosphinic acid functionality can be subdivided into two groups based on their *in vivo* properties (group I: full inhibition of TLOS_R at a narrow therapeutic range; group II: partial inhibition of TLOS_R at a broad therapeutic range). We have not formally established the therapeutic range as defined by the potency to produce side effects compared with the potency to inhibit TLOS_R. However, the span between doses producing some 50% inhibition of TLOS_R and the lowest dose producing visible side effects in dogs is lower for baclofen than for lesogaberan (Lehmann *et al.*, 2009). The prediction that a group II agonist (lesogaberan) does not produce typical central GABA_B-related side effects at therapeutic exposures has now been confirmed in humans (Boeckxstaens *et al.*, 2011). Consequently, the suggestion that there is a difference with respect to therapeutic window between the group I and II agonists reported here is speculative and based on extrapolation from comparisons between baclofen and lesogaberan.

The substituent on the phosphorus atom dictates whether any compound of the current series is a group I or II compound so that 3-aminopropyl(methyl)phosphinic acids belong to group I, while 3-aminopropylphosphinic acids belong to group II agonists (provided that other structural features are compatible with GABA_B receptor agonism). However, there is one important exception to this classification in that 3-aminopropylphosphinic acids with a large 2-substituent such as 4-chlorophenyl (compound 18) have a profile similar to the 3-aminopropyl(methyl)phosphinic acids. This conclusion is limited by the fact that it is only based on the high efficacy and potency (in relation to the *in vitro* potency) on TLOS_R in the dog of compounds 18 and 19. We propose that the critical difference between group I and II agonists can be explained by the affinity of group II but not group I for the GAT, a hypothesis consistent with all results obtained in our study. Thus, methylation of the phosphorous atom, or a large substituent in the 2-position of

Table 5

Pharmacokinetic parameters for GABA_B receptor agonists in female rats following i.v. and p.o. dosing, individual data or mean $\pm$ SD

Compound	Dose ($\mu\text{mol}\cdot\text{kg}^{-1}$) i.v./p.o.	N i.v. + p.o.	CL ($\text{mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$)	$t_{1/2}$ (h)	V_{ss} ($\text{L}\cdot\text{kg}^{-1}$)	F (%)
Group II						
2	2/4	2 + 3	71, 119	0.09, 0.18	0.40, 0.96	33, 41, 42
4	7	4 + 5	15 $\pm$ 2	1.8 $\pm$ 0.3	1.1 $\pm$ 0.1	77 $\pm$ 13
8	3	2 + 2	23, 28	3.0, 3.5	2.9, 3.6	89, 97
10	7	2 + 3	13, 12	2.8, 2.8	2.2, 2.3	79, 110, 119
14	7	3 + 3	26, 28, 30	1.9, 1.8, 1.6	2.8, 2.9, 2.5	72, 79, 94
Group I						
13	0.5	2 + 3	13, 13	0.34, 0.34	0.38, 0.34	74, 89

CL, clearance; $t_{1/2}$, half-life; V_{ss} , volume of distribution at steady state; F, oral availability.

3-aminopropylphosphinic acids, prevents binding to the GAT while binding to the GABA_B receptor is retained. Sequestration of group II agonists in neural cells reduces the extracellular levels in the brain and protects against side effects caused by excessive central GABA_B activation. Systemic pharmacokinetics can be excluded as a differentiating factor since they are broadly comparable for group I and II agonists in two different species. Incidentally, while compounds 1–3 have been widely used in different *in vivo* experiments before, this is to our knowledge the first report on their pharmacokinetics. The discussion below attempts to join all results into a unifying hypothesis to explain the *in vivo* differences between group I and II GABA_B receptor agonists.

Species differences

The results in the present study are based on studies performed on human recombinant GABA_B receptors, rat and dog brain membranes, as well as *in vivo* experiments in the rat, mouse, ferret and dog. There were several reasons for using different species. Rats were used in most experiments since those assays were developed and optimized for rats. Mice were used in hypothermia experiments after systemic administration of drugs since we have used this species for this purpose in several other studies with the aim of having a homogenous data base. Human recombinant GABA_B receptors were utilized for translational purposes. Finally, as TLOSRs would be difficult to measure in rodents, and since indirect evidence suggests that they lack this reflex, dogs were used. In this context, some experiments were done using dog brain membranes to verify that the agonists indeed do have similar effects on canine GABA_B receptors as on human and rat GABA_B receptors. While the use of many different species in different models may be viewed as a disadvantage, it can just as well be considered a strength since it demonstrates to some extent that there is universal and not species-specific validity of the results. In order to be able to make any cross-species comparisons, the similarities of the GABA_B receptors between species have to be assessed. The GABA_B receptor is one of the most highly conserved GPCRs, and the amino acid residues of GABA_{B1} participating in binding of ligands

(Lehmann *et al.*, 2010) are identical in humans, dogs, rats and mice [sequence alignment using ClustalX; sequences retrieved from Swissprot (human, rat, mouse) and REFSEQ (dog)]. Furthermore, as shown in the present work, displacement of [³H]-GABA from dog and rat brain membranes was almost identical for most agonists tested. Previous work has shown that baclofen has, at comparable doses, very similar potency in dogs (Lehmann *et al.*, 1999), ferrets (Blackshaw *et al.*, 1999), cats (Liu *et al.*, 2002) and humans (Lidums *et al.*, 2000; Zhang *et al.*, 2002) as an inhibitor of TLOSRs. In addition, lesogaberan has similar effects on TLOSR in dogs and humans at comparable plasma exposures (Lehmann *et al.*, 2010). It therefore seems reasonable to extrapolate results obtained in one species to the other species. Indeed, apart from expected differences related to body mass-dependent disparities in pharmacokinetics, the only species differences that have been demonstrated in this regard pertain to the expression of some splice variants in the rat but not in humans (Pfaff *et al.*, 1999). However, these variants have a pharmacology similar to that of the other splice variants (Pfaff *et al.*, 1999).

Different selectivity for the GABA_B versus GABA_A receptor or for GABA_{B1} splice variants does not explain the disparities between group I and II agonists

Both group I and II agonists were found to be highly selective for GABA_B receptors, but the former had a considerably higher selectivity for the GABA_B compared with the GABA_A receptor. However, the group II agonist lesogaberan was completely selective for the GABA_B receptor at the doses administered *in vivo* as shown by the absence of an effect of the compound on body temperature in GABA_{B1}^{-/-} mice (Lehmann *et al.*, 2009). In addition, the GABA_B receptor antagonist CGP62349 abolished the effects of lesogaberan in wild-type mice (Lehmann *et al.*, 2009). Others have shown that compound 2 is less selective for the GABA_B receptor than its 3-aminopropyl(methyl)phosphinic acid congener compound 1 (Froestl *et al.*, 1995). The most likely explanation for the lower GABA_B selectivity of group II compounds is that the

properties of the phosphinic acid group are more similar to the carboxylic acid group of GABA than the methylphosphinic acid group. GABA is only slightly more selective for the GABA_B versus the GABA_A receptor (Froestl *et al.*, 1995), so it is clear that the phosphinic, and particularly so the methylphosphinic acid group, confers GABA_B receptor selectivity. There are no data to suggest that the differential selectivity between group I and II agonists for GABA_B/GABA_A has any relevance to their different *in vivo* profiles.

Although some minor disparities were observed, there was no consistent difference between group I and II agonists as regards selectivity for different human recombinant GABA_{B1} splice variants, which suggests that the differences in terms of the *in vivo* effects are unrelated to differential activation of splice variants. This set of data also demonstrates that the potency of the agonists on the splice variants is virtually identical to that on the two predominant splice variants, the GABA_{B1(a)} and GABA_{B1(b)}. Furthermore, it should be underscored that both group I and II compounds used in the present study are all full agonists *in vitro* so differences in terms of efficacy at the receptor level can be excluded in the explanation of disparate *in vivo* profiles. In fact, we found that the group I agonist 16, which is a partial agonist *in vitro* (Froestl *et al.*, 1995; Knight and Bowery, 1996), acted as a full agonist in the dog TLOS_R model. This suggests that there is a large GABA_B receptor reserve, and that only a fraction of the receptors has to be stimulated to produce full inhibition of TLOS_Rs.

Penetration across the blood–brain barrier does not determine the in vivo characteristics of GABA_B receptor agonists

Any differences between group I and II agonists, which are related to a divergent ability to cross the blood–brain barrier, would be negated after central administration of the compounds. Using two pairs of group I and II agonists (compound 7 and 8, and 9 and 10), we found that there was an extremely large difference in the ability to evoke hypothermic effects in rats. The *in vitro* activity was similar within the pairs, but the group I agonists were 2–3 orders of magnitude more active when given i.c.v. This would indicate that the difference in activity with respect to CNS side effects seen between group I and II agonists is related to the disposition of the compound within the CNS and not to the permeation across the blood–brain barrier.

Efficient sequestration of group II but not group I agonists in neural cells provides an explanation for differences in in vivo properties of the compounds

The hypothesis that group II agonists are sequestered by neural cells was investigated directly using rat brain membrane GAT and cerebrocortical slices. All group II agonists evaluated displaced GABA from GAT, while none of the group I ligands had any effect. Consistent with this, the uptake of group II compounds in brain slices was considerably more extensive than that of compound 1. Incidentally, piperidiny-3-phosphinic acids, which have no affinity for any GABA receptor, are only active as GABA transporter inhibitors if they carry a phosphinic acid but not a methylphosphinic acid group in the 3-position (Kehler *et al.*, 1999). The *in vitro*

results were corroborated by findings on the CNS distribution of compound 8 (supplementary information online).

The mechanism of action of group I and II agonists on TLOS_Rs

Group I agonists produced full inhibition of TLOS_Rs largely according to their *in vitro* potency. In addition, the dose-response curves appeared regular and monophasic (see also Lehmann *et al.*, 1999 and Blackshaw *et al.*, 1999). In contrast, none of the group II agonists afforded more than 50% inhibition of TLOS_R in dogs even at high doses. Whether they would produce biphasic dose-response curves like lesogaberan (Lehmann *et al.*, 2009) could not be investigated due to limited availability of the compounds.

Baclofen and compounds 2 (Smid *et al.*, 2001) and 14 (Lehmann *et al.*, 2009) inhibit tension-induced firing of ferret gastric vagal mechanoreceptors *in vitro*. Such an effect is in agreement with the dense expression of GABA_{B1} in retrogradely labelled gastric neurons of the ferret nodose ganglion (Smid *et al.*, 2001). This forms a possible morphological correlate to the proposed peripheral actions of group II agonists in inhibiting TLOS_R.

Given the considerations above, the dissimilarities in dose-response curves on TLOS_Rs for group I and II agonists may be explained in the following way. Group II agonists act at moderate doses exclusively on gastric endings of vagal mechanoreceptors. The relatively low potency and/or efficacy of GABA_B agonists on GABA_B receptors in vagal afferents (Smid *et al.*, 2001) is compatible with the moderate effect on TLOS_Rs, even if the plasma concentrations were sufficient to fully activate GABA_B receptors in recombinant systems, or to saturate native brain GABA_B receptors. In contrast, group I agonists act mainly on central GABA_B receptors, possibly those that may be expressed on central terminations of vagal afferents. Their effect is proposedly explained by inhibition of release of excitatory transmitters leading to a dampening of the vagovagal pathway underlying TLOS_R. This notion is also consistent with the finding that baclofen given to ferrets *in vivo* inhibits gastric vagal tension-sensitive afferents and efferents, and that the latter are more sensitive (Partosoedarso *et al.*, 2001). This clearly suggests that a central effect is required to achieve maximal inhibition of the efferent response that controls TLOS_Rs.

Baclofen and compound 2 are antitussive in different animal models (Bolser *et al.*, 1993, 1994; Chapman *et al.*, 1993; Hey *et al.*, 1995). Their mechanism of action has been extensively investigated, and it has been suggested that baclofen has a central site of antitussive action, while compound 2 inhibits cough peripherally. Such a suggestion, although limited by the fact that only one group II agonist was evaluated, agrees well with the present findings.

There is now supportive translational data from clinical trials to show not only that lesogaberan (compound 10) reduces TLOS_R and gastro-oesophageal reflux (Boeckxstaens *et al.*, 2010a; b), but, more importantly, a 1 month phase IIa study (Boeckxstaens *et al.*, 2010a) demonstrated that lesogaberan provides symptomatic relief in GORD patients with an incomplete response to proton pump inhibitors in the absence of the CNS side effects of baclofen (a group I compound). Together, the clinical studies provide evidence for a mechanistic link between inhibition of TLOS_R and reflux

episodes on the one hand, and amelioration of GORD-related symptoms on the other. A shortcoming with the group II GABA_B receptor agonists as reflux inhibitors is that their postulated superior therapeutic index compared with baclofen occurs at the expense of a lower level of inhibition of TLOS and reflux. While this is a reasonable compromise for a GORD therapy where a benign side effect profile is of paramount importance, additional clinical studies are needed to determine both the minimal level of TLOS inhibition required to achieve a clinically significant symptomatic response as well as identification of target patient population(s). For instance, patients with functional heartburn (typical symptoms not associated with reflux) are not expected to benefit from a reflux inhibitor, and they may constitute a significant proportion of the incomplete responders to proton pump inhibitor therapy (Zerbib *et al.*, 2006). In contrast, patients whose main symptom is regurgitation may be an ideal population for a reflux inhibitor therapy. Similarly, volume regurgitation in infants, which presents a major clinical challenge for which no effective treatment exists, may be another population in which reflux inhibitors may afford beneficial effects (Omari *et al.*, 2006).

In summary, we have shown that GABA_B receptor agonists can be divided into two functional groups. The major drawback of baclofen is its central side effects, and this, together with the lack of receptor subtype selective compounds, has encouraged the discovery of new GABA_B receptor agonists. The present report suggests that group II GABA_B agonists may have a therapeutic utility in GORD (Kuo and Holloway, 2010). The finding that 3-aminopropylphosphonic acids generally have high oral availability and favourable plasma half-life makes these compounds highly interesting from a drug discovery and development point of view.

Acknowledgements

This study was partly supported by AstraZeneca R&D. PS and SSO were supported by Competitive Research Funding of Pirkanmaa Hospital District, and LAB by an Australian National Health and Medical Research Council Principal Research Fellowship. The expert technical assistance of Susanne Staaf, Anita Fredriksson, Irma Rantamaa and Esther Staunton is gratefully acknowledged. The radiolabelled compounds were synthesized by Roger Simonsson, AstraZeneca R&D Mölndal and Bengt Åsling is acknowledged for help with bioinformatic searches.

Conflicts of interest

LAB receives financial research support from AstraZeneca.

References

- Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1–S324.
- Alstermark C, Amin K, Dinn SR, Elebring T, Fjellström O, Fitzpatrick K *et al.* (2008). Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABA_B) receptor agonists as gastroesophageal reflux inhibitors. J Med Chem 51: 4315–4320.
- Blackshaw LA, Staunton E, Lehmann A, Dent J (1999). Inhibition of transient LOS relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 277: G867–G874.
- Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J *et al.* (2010a). Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139: 409–417.
- Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M (2010b). Effect of lesogaberan, a novel GABA_B receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 31: 1208–1217.
- Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M *et al.* (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 60: 1182–1188.
- Bolser DC, Aziz SM, DeGennaro FC, Kreutner W, Egan RW, Siegel MI *et al.* (1993). Antitussive effects of GABA-B agonists in the cat and guinea pig. Br J Pharmacol 110: 491–495.
- Bolser DC, DeGennaro FC, O'Reilly S, Chapman RW, Kreutner W, Egan RW *et al.* (1994). Peripheral and central sites of action of GABA-B agonists to inhibit the cough reflex in the cat and guinea pig. Br J Pharmacol 113: 1344–1348.
- Brändén L, Fredriksson A, Harring E, Jensen J, Lehmann A (2010). The novel, peripherally restricted GABA_B receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs. Eur J Pharmacol 634: 138–141.
- Chapman RW, Hey JA, Rizzo CA, Bolser DC (1993). GABA_B receptors in the lung. Trends Pharmacol Sci 14: 26–29.
- Cheng Y-C, Prusoff WH (1973). Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (I₅₀). Biochem Pharmacol 22: 3099–3108.
- Dingwall JG, Ehrenfreund J, Hall RG (1989). Diethoxymethylphosphonates and phosphinates. Intermediates for the synthesis of α,β- and X aminoalkylphosphonous acids. Tetrahedron 45: 3787–3808.
- Ekstrand J (2002). Nucleotide sequences. US Patent 6,465,213.
- Froestl W, Mickel SJ, Hall RG, von Sprecher G, Strub D, Baumann PA *et al.* (1995). Phosphonic acid analogues of GABA. 1. New potent and selective GABA_B agonists. J Med Chem 38: 3297–3312.
- van Herwaarden MA, Samsom M, Smout AJ (2000). Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LOS relaxations. Gastroenterology. 119: 1439–1446.
- Hey JA, Mingo G, Bolser DC, Kreutner W, Krobatsch D, Chapman RW (1995). Respiratory effects of baclofen and 3-aminopropylphosphonic acid in guinea-pigs. Br J Pharmacol 114: 735–738.
- Kehler J, Stensbol TB, Krogsgaard-Larsen P (1999). Piperidiny-3-phosphonic acids as novel uptake inhibitors of the neurotransmitter γ-aminobutyric acid (GABA). Bioorg Med Chem Lett 9: 811–814.

- Knight AR, Bowery NG (1996). The pharmacology of adenylyl cyclase modulation by GABA_B receptors in rat brain slices. *Neuropharmacology* 35: 703–712.
- Kuo P, Holloway RH (2010). Beyond acid suppression: new pharmacologic approaches for treatment of GORD. *Curr Gastroenterol Rep* 12: 175–180.
- Lehmann A, Antonsson M, Bremner-Danielsen M, Flärdh M, Hansson-Brändén L, Kärrberg L (1999). Activation of the GABA_B receptor inhibits transient lower esophageal sphincter relaxations in dogs. *Gastroenterology* 117: 1147–1154.
- Lehmann A, Holmberg AA, Bhatt U, Bremner-Danielsen M, Brändén L, Elg S *et al.* (2005). Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice. *Br J Pharmacol* 146: 89–97.
- Lehmann A, Antonsson M, Holmberg AA, Blackshaw LA, Brändén L, Bräuner-Osborne H *et al.* (2009). R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABA_B receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. *J Pharmacol Exp Ther* 331: 504–512.
- Lehmann A, Jensen JM, Boeckxstaens GE (2010). GABA_B receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. *Adv Pharmacol* 58: 287–313.
- Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH (2000). Control of transient lower esophageal sphincter relaxations and reflux by the GABA_B agonist baclofen in normal subjects. *Gastroenterology* 118: 7–13.
- Liu J, Pehlivanov N, Mittal RK (2002). Baclofen blocks LOS relaxation and crural diaphragm inhibition by esophageal and gastric distension in cats. *Am J Physiol* 283: G1276–G1281.
- Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J (1995). Transient lower esophageal sphincter relaxation. *Gastroenterology* 109: 601–610.
- Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP (2006). Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. *J Pediatr* 149: 468–474.
- Partosoedarso ER, Young RL, Blackshaw LA (2001). GABAB receptors on vagal afferent pathways: peripheral and central inhibition. *Am J Physiol* 280: G658–G668.
- Paxinos G, Watson C (1982). *The Rat Brain in Stereotoxic Coordinates*. Academic Press: New York.
- Pfaff T, Malitschek B, Kaupmann K, Prezeau L, Pin JP, Bettler B *et al.* (1999). Alternative splicing generates a novel isoform of the rat metabotropic GABA(B)R1 receptor. *Eur J Neurosci* 112: 874–882.
- Piche T, Zerbib F, Varannes SB, Cherbut C, Anini Y, Roze C *et al.* (2000). Modulation by colonic fermentation of LOS function in humans. *Am J Physiol* 278: G578–G584.
- Shank RP, Baldy WJ, Mattucci LC, Villani FJ (1990). Ion and temperature effects on the binding of gamma-aminobutyrate to its receptors and the high-affinity transport system. *J Neurochem* 54: 2007–2015.
- Smid S, Young R, Cooper N, Blackshaw LA (2001). GABA(B)R expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. *Am J Physiol* 281: G1494–G1501.
- Stakeberg J, Lehmann A (1999). Influence of different intragastric stimuli on triggering of transient lower oesophageal sphincter relaxation in the dog. *Neurogastroenterol Motil* 11: 125–132.
- van Wijk MP, Benninga MA, Davidson GP, Haslam R, Omari TI (2010). Small volumes of feed can trigger transient lower esophageal sphincter relaxation and gastroesophageal reflux in the right lateral position in infants. *J Pediatr* 156: 744–748.
- Wu JC-Y, Mui LM, Cheung CM-Y, Chan Y, Sung JJ-Y (2007). Obesity is associated with increased transient lower esophageal sphincter relaxation. *Gastroenterology* 132: 883–889.
- Zerbib F, Roman S, Ropert A, Bruley des Varannes S, Poudereux P, Chaput U *et al.* (2006). Esophageal pH-impedance monitoring and symptom analysis in GORD: a study in patients off and on therapy. *Am J Gastroenterol* 101: 1956–1963.
- Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH (2002). Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease. *Gut* 50: 19–24.